Shares of Waldencast PLC (NASDAQ:WALD – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $4.4167.
Several analysts recently issued reports on the stock. Canaccord Genuity Group reduced their price target on shares of Waldencast from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, November 25th. Telsey Advisory Group lowered shares of Waldencast from an “outperform” rating to a “market perform” rating and set a $3.00 price objective on the stock. in a research note on Tuesday, November 25th. Jefferies Financial Group assumed coverage on shares of Waldencast in a research report on Wednesday, January 14th. They set a “buy” rating and a $2.00 target price for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Waldencast in a report on Wednesday, January 21st.
Check Out Our Latest Stock Analysis on Waldencast
Institutional Inflows and Outflows
Waldencast Price Performance
Shares of Waldencast stock opened at $1.80 on Monday. The business has a 50-day simple moving average of $1.78 and a 200 day simple moving average of $1.88. Waldencast has a one year low of $1.45 and a one year high of $3.54. The company has a quick ratio of 0.67, a current ratio of 1.53 and a debt-to-equity ratio of 0.32.
Waldencast (NASDAQ:WALD – Get Free Report) last announced its quarterly earnings data on Monday, November 24th. The company reported ($0.69) EPS for the quarter. The business had revenue of $66.14 million during the quarter. As a group, analysts anticipate that Waldencast will post -0.14 earnings per share for the current fiscal year.
About Waldencast
Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians. The company also offers clean makeup products under the Milk Makeup brand. It sells its products to dermatologists, plastic surgeons, and other physicians who focuses on aesthetic and therapeutic skincare, including physicians on site at medical spas, through its direct sales force, as well as through distribution partners.
Read More
- Five stocks we like better than Waldencast
- The gold chart Wall Street is terrified of…
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- New gold price target
Receive News & Ratings for Waldencast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waldencast and related companies with MarketBeat.com's FREE daily email newsletter.
